SRRA Sierra Oncology Inc.

12.32
-0.75  -6%
Previous Close 13.07
Open 13.1
Price To Book 15.6
Market Cap 23,003,990
Shares 1,867,207
Volume 19,882
Short Ratio
Av. Daily Volume 68,669
Stock charts supplied by TradingView

NewsSee all news

  1. Sierra Oncology Announces Reverse Stock Split

    - Preferred shares issued in recently completed $103M financing to convert to common shares -- Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement - VANCOUVER, Jan. 22, 2020

  2. Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

    - New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting - - Analyst & Investor Event

  3. Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH

    - Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8th - - Data highlighting decreased transfusion requirements for patients treated with momelotinib directly compared to

  4. Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors

    VANCOUVER, Nov. 26, 2019 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with

  5. Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis

    - MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen -- Targeting enrollment of 180 symptomatic and anemic patients

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Discontinued following poor efficacy - June 2016
PNT2258
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) - cancer
Development suspended - June 2016
PNT2258
Richter's Transformation
Phase 1/2 preliminary data ASCO June 1, 2019 noted stable disease rate of 32%.
SRA737
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
Phase 1/2 preliminary data of ORR 30% at ASCO June 1, 2019. 8am.
SRA737 + Low-Dose Gemcitabine
Solid Tumors
Phase 3 trial initiation announced November 20, 2019 with top-line data due 4Q 2021.
Momelotinib - MOMENTUM
Myelofibrosis

Latest News

  1. Sierra Oncology Announces Reverse Stock Split

    - Preferred shares issued in recently completed $103M financing to convert to common shares -- Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement - VANCOUVER, Jan. 22, 2020

  2. Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

    - New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting - - Analyst & Investor Event

  3. Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH

    - Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8th - - Data highlighting decreased transfusion requirements for patients treated with momelotinib directly compared to

  4. Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors

    VANCOUVER, Nov. 26, 2019 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with

  5. Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis

    - MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen -- Targeting enrollment of 180 symptomatic and anemic patients

  6. Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference

    - "Building Momentum for Patients with Myelofibrosis" scheduled for 6:00 p.m. GMT on November 20, 2019 - VANCOUVER, Nov. 14, 2019 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug

  7. Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib

    - Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra -- Amendments become effective upon Sierra Oncology closing a qualified financing - VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Sierra

  8. Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib

    - Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra -- Amendments become effective upon Sierra Oncology closing a qualified financing - VANCOUVER, Nov. 7, 2019 /CNW/ - Sierra

  9. Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants

    VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a

  10. Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants

    VANCOUVER, Nov. 6, 2019 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a

  11. Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants

    VANCOUVER, Nov. 6, 2019 /CNW/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a

  12. Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019

    - New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients are nearly 10-times more likely to remain transfusion free compared to ruxolitinib treated patients - VANCOUVER, Nov.

  13. Sierra Oncology Reports Third Quarter 2019 Results

    - MOMENTUM Phase 3 myelofibrosis clinical trial anticipated to launch in Q4 2019 - VANCOUVER, Nov. 4, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing